Literature DB >> 10323789

Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.

J P Bossavy1, K S Sakariassen, K Rübsamen, C Thalamas, B Boneu, Y Cadroy.   

Abstract

Polyethylene glycol (PEG)-hirudin is a derivative of hirudin with a long plasma half-life. We have compared the efficacy of PEG-hirudin with unfractionated heparin (UH) in preventing arterial thrombosis. Arterial thrombus formation was induced ex vivo in 12 healthy human volunteers by exposing a tissue factor-coated coverslip positioned in a parallel-plate perfusion chamber to flowing nonanticoagulated human blood drawn directly from an antecubital vein at an arterial wall shear rate of 2600 s-1 for 3.5 minutes. PEG-hirudin, UH, or saline (as control) were administered ex vivo through a heparin-coated mixing device positioned proximal to the perfusion chamber. Platelet and fibrin deposition was quantified by immunoenzymatic measure of the P-selectin and D-dimer content of dissolved plasmin-digested thrombi, respectively. UH was administered to a plasma concentration of 0.35 IU/mL. This concentration prolonged the activated partial thromboplastin time from 32+/-1 seconds to 79+/-4 seconds (P<0.01). UH did not significantly prevent platelet deposition. However, fibrin deposition was reduced by 39% (P<0.05). PEG-hirudin in plasma concentrations of 0.5, 2.5, and 5 microg/mL prolonged the activated partial thromboplastin time to 48+/-2, 87+/-4, and 118+/-4 seconds, respectively. In contrast to UH, PEG-hirudin prevented both platelet and fibrin deposition in a dose-dependent manner with a >80% reduction at 5 microg/mL (P<0.01). Furthermore, the plasma level of PEG-hirudin required to significantly prevent fibrin deposition (0.5 microg/mL) corresponded to a much shorter prolongation of activated partial thromboplastin time (48+/-2 seconds) than that needed for UH (79+/-4 seconds). Thus, our results are compatible with the view that thrombin is greatly involved in recruitment of platelets in evolving thrombi, and that PEG-hirudin is an effective agent for preventing arterial thrombosis in a human ex vivo experimental model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323789     DOI: 10.1161/01.atv.19.5.1348

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  3 in total

1.  Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.

Authors:  M Moser; J Ruef; K Peter; B Kohler; D C Gulba; N Paterna; T Nordt; W Kübler; C Bode
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

Review 2.  Development and hemocompatibility testing of nitric oxide releasing polymers using a rabbit model of thrombogenicity.

Authors:  Terry C Major; Hitesh Handa; Gail M Annich; Robert H Bartlett
Journal:  J Biomater Appl       Date:  2014-06-16       Impact factor: 2.646

Review 3.  The impact of blood shear rate on arterial thrombus formation.

Authors:  Kjell S Sakariassen; Lars Orning; Vincent T Turitto
Journal:  Future Sci OA       Date:  2015-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.